Vistagen Therapeutics Inc (VTGN)

$0.71 +0.02 (3.52%)
Market Cap 27.80M
Revenue (ttm) 490,000.00
Net Income (ttm) -51.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,493.88%
Debt to Equity Ratio 0.00
Volume 1,565,395
Avg Vol 3,065,538
Day's Range N/A - N/A
Shares Out 39.50M
Stochastic %K 40%
Beta 0.31
Analysts Hold
Price Target $0.95

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
mark31
mark31 Jan. 14 at 6:09 PM
$VTGN
0 · Reply
mb0157
mb0157 Jan. 14 at 5:54 PM
$VTGN. Pay close attention to those bollinget bands. Something is coming!!
1 · Reply
LORAXX
LORAXX Jan. 14 at 5:42 PM
$VTGN
0 · Reply
nightstocker15
nightstocker15 Jan. 14 at 5:34 PM
$VTGN over double the market cap in cash alone! Thats with getting the whole pipeline for free! Don’t be the one telling your friends at parties you could’ve gotten in once this thing has doubled. Be the one who acted on the opportunity and can sit back and watch your position swell. Trust me, I hear that all the time! 🥃🔥🙌💰
1 · Reply
mimiwor
mimiwor Jan. 14 at 5:30 PM
$VTGN ha
0 · Reply
mimiwor
mimiwor Jan. 14 at 5:14 PM
$VTGN I usually don’t remember my dreams, but last night I had this one… She was heading $20 for no reason.
1 · Reply
MoffaMan
MoffaMan Jan. 14 at 4:50 PM
$VTGN SP will start moving up next week after The "30-day stock buyback rule takes affect
0 · Reply
BootyCheeks
BootyCheeks Jan. 14 at 4:46 PM
$VTGN we’re sniffing a dollar here soon.
1 · Reply
BobbyBalentino
BobbyBalentino Jan. 14 at 4:42 PM
$VTGN $1.50 stock with cash on hand CMON NOW PUMP
0 · Reply
CapitalGains007
CapitalGains007 Jan. 14 at 4:42 PM
$VTGN $AABB yall need some VTGN
0 · Reply
Latest News on VTGN
Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Dec 17, 2025, 12:42 PM EST - 4 weeks ago

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Dec 17, 2025, 8:30 AM EST - 4 weeks ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Nick Tressler as Chief Financial Officer

Dec 1, 2025, 8:30 AM EST - 6 weeks ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 26, 2025, 8:30 AM EST - 7 weeks ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026

Nov 18, 2025, 7:45 AM EST - 2 months ago

Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026

Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 7:01 PM EST - 2 months ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 13, 2025, 4:30 PM EST - 2 months ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 10, 2025, 8:30 AM EST - 2 months ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 5, 2025, 8:30 AM EST - 2 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Nov 3, 2025, 8:30 AM EST - 2 months ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Paul Edick to its Board of Directors

Oct 29, 2025, 8:30 AM EDT - 2 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Oct 16, 2025, 8:30 AM EDT - 3 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 8:30 AM EDT - 4 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Aug 8, 2025, 2:13 PM EDT - 5 months ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Aug 7, 2025, 4:30 PM EDT - 5 months ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 31, 2025, 8:30 AM EDT - 5 months ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 6 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jul 15, 2025, 8:30 AM EDT - 6 months ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 25, 2025, 8:30 AM EDT - 7 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 6:49 PM EDT - 7 months ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 17, 2025, 4:30 PM EDT - 7 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 12, 2025, 8:30 AM EDT - 7 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Jun 2, 2025, 8:30 AM EDT - 8 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 28, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Apr 17, 2025, 8:30 AM EDT - 9 months ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 19, 2025, 8:30 AM EDT - 10 months ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Mar 4, 2025, 8:30 AM EST - 11 months ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 20, 2025, 8:30 AM EST - 11 months ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Feb 14, 2025, 6:19 PM EST - 11 months ago

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Feb 13, 2025, 8:47 PM EST - 11 months ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 13, 2025, 4:30 PM EST - 11 months ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 6, 2025, 8:30 AM EST - 1 year ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Feb 5, 2025, 8:30 AM EST - 1 year ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 14, 2025, 8:30 AM EST - 1 year ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Jan 10, 2025, 8:30 AM EST - 1 year ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Nov 10, 2024, 7:43 AM EST - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Nov 7, 2024, 4:20 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Nov 5, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Oct 15, 2024, 7:25 AM EDT - 1 year ago

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Oct 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Sep 23, 2024, 8:30 AM EDT - 1 year ago

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Aug 13, 2024, 7:05 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Aug 13, 2024, 4:21 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Jul 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

Jun 11, 2024, 6:41 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

mark31
mark31 Jan. 14 at 6:09 PM
$VTGN
0 · Reply
mb0157
mb0157 Jan. 14 at 5:54 PM
$VTGN. Pay close attention to those bollinget bands. Something is coming!!
1 · Reply
LORAXX
LORAXX Jan. 14 at 5:42 PM
$VTGN
0 · Reply
nightstocker15
nightstocker15 Jan. 14 at 5:34 PM
$VTGN over double the market cap in cash alone! Thats with getting the whole pipeline for free! Don’t be the one telling your friends at parties you could’ve gotten in once this thing has doubled. Be the one who acted on the opportunity and can sit back and watch your position swell. Trust me, I hear that all the time! 🥃🔥🙌💰
1 · Reply
mimiwor
mimiwor Jan. 14 at 5:30 PM
$VTGN ha
0 · Reply
mimiwor
mimiwor Jan. 14 at 5:14 PM
$VTGN I usually don’t remember my dreams, but last night I had this one… She was heading $20 for no reason.
1 · Reply
MoffaMan
MoffaMan Jan. 14 at 4:50 PM
$VTGN SP will start moving up next week after The "30-day stock buyback rule takes affect
0 · Reply
BootyCheeks
BootyCheeks Jan. 14 at 4:46 PM
$VTGN we’re sniffing a dollar here soon.
1 · Reply
BobbyBalentino
BobbyBalentino Jan. 14 at 4:42 PM
$VTGN $1.50 stock with cash on hand CMON NOW PUMP
0 · Reply
CapitalGains007
CapitalGains007 Jan. 14 at 4:42 PM
$VTGN $AABB yall need some VTGN
0 · Reply
CapitalGains007
CapitalGains007 Jan. 14 at 4:41 PM
$VTGN SEND IT
0 · Reply
mark31
mark31 Jan. 14 at 4:39 PM
$VTGN starting to get found
0 · Reply
marketCaptain
marketCaptain Jan. 14 at 4:22 PM
$VTGN Its about so go full send
0 · Reply
nightstocker15
nightstocker15 Jan. 14 at 4:21 PM
$VTGN break .80! Let’s F’n go!
0 · Reply
CapitalGains007
CapitalGains007 Jan. 14 at 4:20 PM
$VTGN here is comes
0 · Reply
Sindi1987
Sindi1987 Jan. 14 at 4:19 PM
$VTGN this should be above 1 by now come on !!!!!!
0 · Reply
NBI
NBI Jan. 14 at 4:14 PM
$VTGN wants to run so badly. Give it some news and love
1 · Reply
BootyCheeks
BootyCheeks Jan. 14 at 2:20 PM
$VTGN let’s print some money.
0 · Reply
CapitalGains007
CapitalGains007 Jan. 14 at 2:17 PM
$VTGN this needs to get back to $5
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 1:16 PM
Enter: $VTGN Calls Strike Price: $1 Expiry Date: FEB 20 2026 Buy in Price: $0.05 - $0.10 Sell Price: $0.10 Profit : +101% (Turn every $1 into $2.01) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
BioBum
BioBum Jan. 14 at 12:12 PM
$VTGN my dear ole vistagina
1 · Reply
Vengeance2026
Vengeance2026 Jan. 14 at 12:32 AM
$VTGN VistaGen's employees never gave up. We believe that after passing through the dark tunnel, we will soar dazzlingly, spraying light.
1 · Reply